The Rho kinase inhibitor fasudil augments the number of functional endothelial progenitor cells in ex vivo cultures

International Journal of Molecular Medicine

Volumn 28, Issue 3, 2011, Pages 357-363

  O, Eunju ^a   Ahn, Hyun Young ^a   Kim, Hyun Kyung ^a   You, Ji Chang ^a   Shin, Jong Chul ^a   Joe, Young A E ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Endothelial progenitor cell; Fasudil; Ischemia; Neovascularization; Rho kinase inhibitor

Indexed keywords

FASUDIL; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; SIMVASTATIN; STROMAL CELL DERIVED FACTOR 1; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL COUNT; CELL DIFFERENTIATION; CELL MIGRATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; ENDOTHELIAL PROGENITOR CELL; EX VIVO STUDY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VIVO STUDY; MALE; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL; TREATMENT RESPONSE;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; ANIMALS; CELL ADHESION; CELL PROLIFERATION; CELLS, CULTURED; CHEMOKINE CXCL12; ENDOTHELIAL CELLS; HINDLIMB; HUMANS; ISCHEMIA; MALE; MICE; MICE, INBRED BALB C; MODELS, ANIMAL; NEOVASCULARIZATION, PHYSIOLOGIC; PROTEIN KINASE INHIBITORS; RHO-ASSOCIATED KINASES; STEM CELL TRANSPLANTATION; STEM CELLS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79959984102     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2011.698     Document Type: Article

References (27)

1. Kalka C, Masuda H, Takahashi T, Kalka-Moll WM, Silver M, Kearney M, Li T, Isner JM and Asahara T: Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. Proc Natl Acad Sci USA 97 3422-3427, 2000. (Pubitemid 30183318)
2. Asahara T, Masuda H, Takahashi T, Kalka C, Pastore C, Silver M, Kearne M, Magner M and Isner JM: Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculo-genesis in physiological and pathological neovascularization. Circ Res 85: 221-228, 1999. (Pubitemid 29377293)
3. Takahashi T, Kalka C, Masuda H, Chen D, Silver M, Kearney M, Magner M, Isner JM and Asahara T: Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat Med 5: 434-438, 1999. (Pubitemid 29180584)
4. Asahara T, Takahashi T, Masuda H, Kalka C, Chen D, Iwaguro H, Inai Y, Silver M and Isner JM: VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J 18: 3964-3972, 1999. (Pubitemid 29335849)
5. Yamaguchi J, Kusano KF, Masuo O, Kawamoto A, Silver M, Murasawa S, Bosch-Marce M, Masuda H, Losordo DW, Isner JM and Asahara T: Stromal cell-derived factor-1 effects on ex vivo expanded endothelial progenitor cell recruitment for ischemic neovascularization. Circulation 107: 1322-1328, 2003. (Pubitemid 36314418)
6. Loirand G, Guerin P and Pacaud P: Rho kinases in cardiovascular physiology and pathophysiology. Circ Res 98: 322-334, 2006.
7. Takemoto M, Sun J, Hiroki J, Shimokawa H and Liao JK: Rho-kinase mediates hypoxia-induced downregulation of endothelial nitric oxide synthase. Circulation 106: 57-62, 2002. (Pubitemid 34747442)
8. Ming XF, Viswambharan H, Barandier C, Ruffieux J, Kaibuchi K, Rusconi S and Yang Z: Rho GTPase/Rho kinase negatively regulates endothelial nitric oxide synthase phosphorylation through the inhibition of protein kinase B/Akt in human endothelial cells. Mol Cell Biol 22: 8467-8477, 2002. (Pubitemid 35397163)
9. Wolfrum S, Dendorfer A, Rikitake Y, Stalker TJ, Gong Y, Scalia R, Dominiak P and Liao JK: Inhibition of Rho-kinase leads to rapid activation of phosphatidylinositol 3-kinase/protein kinase Akt and cardiovascular protection. Arterioscler Thromb Vasc Biol 24: 1842-1847, 2004.
10. Nohria A, Grunert ME, Rikitake Y, Noma K, Prsic A, Ganz P, Liao JK and Creager MA: Rho kinase inhibition improves endothelial function in human subjects with coronary artery disease. Circ Res 99: 1426-1432, 2006. (Pubitemid 44949679)
11. Shimokawa H and Takeshita A: Rho-kinase is an important therapeutic target in cardiovascular medicine. Arterioscler Thromb Vasc Biol 25: 1767-1775, 2005. (Pubitemid 41243442)
12. Liao JK, Seto M and Noma K: Rho kinase (ROCK) inhibitors. J Cardiovasc Pharmacol 50: 17-24, 2007. (Pubitemid 47220442)
13. Dong M, Yan BP, Liao JK, Lam YY, Yip GW and Yu CM: Rho-kinase inhibition: a novel therapeutic target for the treatment of cardiovascular diseases. Drug Discov Today 15: 622-629, 2010.
14. Liao JK: Does it matter whether or not a lipid-lowering agent inhibits Rho kinase? Curr Atheroscler Rep 9: 384-388, 2007.
15. Liu PY, Liu YW, Lin LJ, Chen JH and Liao JK: Evidence for statin pleiotropy in humans: differential effects of statins and ezetimibe on rho-associated coiled-coil containing protein kinase activity, endothelial function, and inflammation. Circulation 119: 131-138, 2009.
16. Dimmeier S, Aicher A, Vasa M, Mildner-Rihm C, Adler K, Tiemann M, Rütten H, Fichtischerer S, Martin H and Zeiher AM: HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J Clin Invest 108: 391-397, 2001. (Pubitemid 32730785)
17. Llevadot J, Murasawa S, Kureishi Y, Uchida S, Masuda H, Kawamoto A, Walsh K, Isner JM and Asahara T: HMG-CoA reductase inhibitor mobilizes bone marrow-derived endothelial progenitor cells. J Clin Invest 108: 399-405, 2001. (Pubitemid 32730786)
18. Jaffe EA, Nachman RL, Becker CG and Minick CR: Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest 52: 2745-2756, 1973.
19. + human cord blood fraction for effective therapeutic vascularization. FASEB J 25: 159-169, 2011.
20. Oh HK, Ha JM, O E, Lee BH, Lee SK, Shim BS, Hong YK and Joe YA: Tumor angiogenesis promoted by ex vivo differentiated endothelial progenitor cells is effectively inhibited by an angiogenesis inhibitor, TK1-2. Cancer Res 67: 4851-4859, 2007. (Pubitemid 46915312)
21. Namkoong S and KIM YM: Therapeutic application of nitric oxide in human diseases. Biomol Ther 18: 351-362, 2010.
22. Riento K and Ridley AJ: Rocks: multifunctional kinases in cell behaviour. Nat Rev Mol Cell Biol 4: 446-456, 2003. (Pubitemid 36648590)
23. Davies SP, Reddy H, Caivano M and Cohen P: Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 351: 95-105, 2000.
24. Balestrieri ML, Giovane A, Milone L, Felice F, Fiorito C, Crudele V, Esposito A, Rossiello P, Minucci PB, Farzati B, Servillo L and Napoli C: Modification of the detrimental effect of TNF-alpha on human endothelial progenitor cells by fasudil and Y27632. J Biochem Mol Toxicol 24: 351-360, 2010.
25. Satoh S, Hitomi A, Ikegaki I, Kawasaki K, Nakazono O, Iwasaki M, Mohri M and Asano T: Amelioration of endothelial damage/dysfunction is a possible mechanism for the neuroprotective effects of Rho-kinase inhibitors against ischemic brain damage. Brain Res Bull 81: 191-195, 2010.
26. Feske SK, Sorond FA, Henderson GV, Seto M, Hitomi A, Kawasaki K, Sasaki Y, Asano T and Liao JK: Increased leukocyte ROCK activity in patients after acute ischemic stroke. Brain Res 1257: 89-93, 2009.
27. Ghiaur G, Lee A, Bailey J, Cancelas JA, Zheng Y and Williams DA: Inhibition of RhoA GTPase activity enhances hematopoietic stem and progenitor cell proliferation and engraftment. Blood 108: 2087-2094, 2006. (Pubitemid 44395025)